Browsing by Author "Hiyaw Abebe"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
Item Echocardiographic Evaluation of Cardiac Abnormalities in Pediatric Hodgkin Lymphoma Patients and Survivors Following Anthracycline Therapy at Tikur Anbessa Specialized Hospital(Addis Ababa University, 2025-11-26) Hiyaw Abebe; Haileyesus Adam; Helen Mintesinot; Hayat AhmedBackground The overall survival of Pediatric Hodgkin Lymphoma has increased tremendously in recent years in both low- and higher-income countries. This trend has been possible by the main background therapeutic agents which are anthracyclines. These group of drugs prove to be highly effective at the cost of both short- and long-term treatment side effects. Cardiac dysfunction is one of the main treatment side effects and can happen in acute and late timeframes. Majority of cardiac dysfunction data come from higher income countries with limited evidence from low- and middle-income countries. In Ethiopia, advanced follow-up modalities and structured patient follow-up is constrained. This limitation requires high quality information yet local data is scarce. Objectives The purpose of this study is to assess the cardiac effects of anthracycline-based chemotherapy using echocardiography in pediatric Hodgkin lymphoma patients and survivors treated at Tikur Anbessa Specialized Hospital. Methods We conducted a hospital based cross-sectional study of Pediatric Hodgkin Lymphoma patients and survivors at Tikur Anbessa Specialized Hospital between 2016-2025 GC. The Medical Record Numbers of the patients were retrieved from paper and electronic Health Management Information System. The medical charts were retrieved. Patient phone numbers were then taken from the medical charts and patients were contacted and informed on the intended study and appointed for their respective dates. Demographic and clinical data including age, sex, weight, height, body surface area, Stage, comorbidities, treatment details and additional therapies such as radiotherapy were recorded from their medical charts. Previous echocardiographic evaluations, including baseline and follow-up data, were reviewed if available, but patients were enrolled regardless of the presence of prior echocardiographic records. Current history and physical examinations were also done once the patients arrived at the evaluation site. An echocardiographic evaluation was provided for all participants using a standardized protocol. The echocardiograms were conducted by pediatric cardiologists blinded to the patients‘ characteristics and outcomes to ensure bjectivity. Each cardiologist was labeled as Pediatric Cardiologist 1 and 2 to facilitate comparative analysis of resultant cardiac abnormalities. The echocardiographic parameters assessed includes 2D measurements, M-mode measurements and Doppler measurements. Additional indices like the Myocardial Performance Index (Tei Index), isovolumic contraction and relaxation times, ejection time, and right ventricular function using TAPSE were also recorded. Pulmonary parameters, including the main, left, and right pulmonary artery dimensions were also assessed. Echocardiography interpretations using age and Body Surface Area were done using Z-scores, wherever applicable. Attributes of the documented patient details and imaging results were assessed for the prevalence of cardiac dysfunction and possible associations between the dependent and independent variables using univariate and multivariable logistic regression. Results There were 500 pediatric Hodgkin lymphoma medical record numbers identified in HMIS, 239 charts were available and 228 had phone numbers. Exclusions were made due to non-functional numbers (80), no answer (16), refusal (21), and absence after appointment (16), resulting in 86 participants. They completed a study echocardiogram in 2025. None had a documented baseline echocardiogram, and only 13/86 (15.1%) had at least one previous echocardiogram (and 3/86 [3.4%] had a second prior echo). At diagnosis, 24.4% (21/86) were 12 years. Most were male (94.2% [81/86]). Stage distribution showed Stage I- 7.0%, II- 32.6%, III- 34.9%, IV- 19.8%. 55.8% were high risk. All patients received anthracyclines (ABVD 85, OEPA 1), with cumulative dose 100–250 mg/m² in 83.7% and >250 mg/m² in 15.1%; about one quarter received radiotherapy. The primary outcome, LV systolic dysfunction, was detected in 10/86 (11.6%). At least one other echocardiographic abnormality occurred in 78/86 (90.0%). Univariate logistic regression showed no statistically significant determinants and multivariable models were unstable due to few events and sparse categories. Conclusion LV systolic dysfunction was identified in 11.6% of the patients and survivors, while 90% had at least one other echocardiographic abnormality. Baseline and longitudinal echocardiographic surveillance were largely absent, and determinant analysis was underpowered to identify independent predictors. These findings support the need to implement a feasible, standardized, risk-adapted cardiac monitoring pathway for pediatric HL patients receiving anthracyclines in this setting.